New molecular players facilitating Mg 2+ reabsorption in the distal convoluted tubule

Kidney International

Volumn 77, Issue 1, 2010, Pages 17-22

  Glaudemans, Bob ^a   Knoers, Nine V A M ^a   Hoenderop, Joost G J ^a   Bindels, René J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidermal growth factor; Epithelial; Genetic renal disease; Tubular epithelium

Indexed keywords

ADENOSINE TRIPHOSPHATASE; EPIDERMAL GROWTH FACTOR; HEPATOCYTE NUCLEAR FACTOR 1; MAGNESIUM; SODIUM CHLORIDE COTRANSPORTER; TRANSIENT RECEPTOR POTENTIAL CHANNEL M;

GENE IDENTIFICATION; GENE MUTATION; HUMAN; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE DISORDER; MEMBRANE POTENTIAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

BIOLOGICAL TRANSPORT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY TUBULES, DISTAL; MAGNESIUM; MAGNESIUM DEFICIENCY;

EID: 72949098818     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.358     Document Type: Short Survey

References (52)

1. Lum G. Hypomagnesemia in acute and chronic care patient populations. Am J Clin Pathol 1992; 97: 827-830.
2. Thompson CB, June CH, Sullivan KM et al. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 1984; 2: 1116-1120.
3. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69: 338-341.
4. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355: 1834-1836.
5. Schrag D, Chung KY, Flombaum C et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97: 1221-1224.
6. Tejpar S, Piessevaux H, Claes K et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8: 387-394.
7. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90: 929-931.
8. Silverman RA, Osborn H, Runge J et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest 2002; 122: 489-497.
9. Gabbe SG. A preliminary report on the intravenous use of magnesium sulphate in puerperal eclampsia. 1925. Am J Obstet Gynecol 1996; 174: 1390-1391.
10. Schwartz R, Spencer H, Welsh JJ. Magnesium absorption in human subjects from leafy vegetables, intrinsically labeled with stable 26Mg. Am J Clin Nutr 1984; 39: 571-576.
11. Fine KD, Santa Ana CA, Porter JL et al. Intestinal absorption of magnesium from food and supplements. J Clin Invest 1991; 88: 396-402.
12. Schweigel M, Martens H. Magnesium transport in the gastrointestinal tract. Front Biosci 2000; 5: D666-D677.
13. Rude RK. Magnesium deficiency: a cause of heterogeneous disease in humans. J Bone Miner Res 1998; 13: 749-758.
14. Rude RK, Gruber HE. Magnesium deficiency and osteoporosis: animal and human observations. J Nutr Biochem 2004; 15: 710-716.
15. Simon DB, Lu Y, Choate KA et al. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 1999; 285: 103-106.
16. Konrad M, Schaller A, Seelow D et al. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 2006; 79: 949-957.
17. Hou J, Renigunta A, Konrad M et al. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest 2008; 118: 619-628.
18. Walder RY, Shalev H, Brennan TM et al. Familial hypomagnesemia maps to chromosome 9q, not to the X chromosome: genetic linkage mapping and analysis of a balanced translocation breakpoint. Hum Mol Genet 1997; 6: 1491-1497.
19. Anast CS, Mohs JM, Kaplan SL et al. Evidence for parathyroid failure in magnesium deficiency. Science 1972; 177: 606-608.
20. Schlingmann KP, Weber S, Peters M et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002; 31: 166-170.
21. Walder RY, Landau D, Meyer P et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 2002; 31: 171-174.
22. Voets T, Nilius B, Hoefs S et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004; 279: 19-25.
23. Cao G, Hoenderop JG, Bindels RJ. Insight into the molecular regulation of the epithelial magnesium channel TRPM6. Curr Opin Nephrol Hypertens 2008; 17: 373-378.
24. Groenestege WM, Thebault S, van der Wijst J et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117: 2260-2267.
25. Geven WB, Monnens LA, Willems JL et al. Isolated autosomal recessive renal magnesium loss in two sisters. Clin Genet 1987; 32: 398-402.
26. Poulsen SS, Nexo E, Olsen PS et al. Immunohistochemical localization of epidermal growth factor in rat and man. Histochemistry 1986; 85: 389-394.
27. Dempsey PJ, Meise KS, Yoshitake Y et al. Apical enrichment of human EGF precursor in Madin-Darby canine kidney cells involves preferential basolateral ectodomain cleavage sensitive to a metalloprotease inhibitor. J Cell Biol 1997; 138: 747-758.
28. Thebault S, Alexander RT, Tiel Groenestege WM et al. EGF increases TRPM6 activity and surface expression. J Am Soc Nephrol 2009; 20: 78-85.
29. Breyer MD, Redha R, Breyer JA. Segmental distribution of epidermal growth factor binding sites in rabbit nephron. Am J Physiol 1990; 259: F553-F558.
30. Glaudemans B, van der Wijst J, Scola RH et al. A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. J Clin Invest 2009; 119: 936-942.
31. Grubbs RD. Intracellular magnesium and magnesium buffering. Biometals 2002; 15: 251-259.
32. Yoshitomi K, Shimizu T, Taniguchi J et al. Electrophysiological characterization of rabbit distal convoluted tubule cell. Pflugers Arch 1989; 414: 457-463.
33. Mennitt PA, Wade JB, Ecelbarger CA et al. Localization of ROMK channels in the rat kidney. J Am Soc Nephrol 1997; 8: 1823-1830.
34. Meij IC, Koenderink JB, van Bokhoven H et al. Dominant isolated renal magnesium loss is caused by misrouting of the Na(+),K(+)-ATPase gamma-subunit. Nat Genet 2000; 26: 265-266.
35. Arystarkhova E, Wetzel RK, Sweadner KJ. Distribution and oligomeric association of splice forms of Na(+)-K(+)-ATPase regulatory gamma-subunit in rat kidney. Am J Physiol Renal Physiol 2002; 282: F393-F407.
36. Meij IC, Koenderink JB, De Jong JC et al. Dominant isolated renal magnesium loss is caused by misrouting of the Na+,K+-ATPase gamma-subunit. Ann N Y Acad Sci 2003; 986: 437-443.
37. Sha Q, Pearson W, Burcea LC et al. Human FXYD2 G41R mutation responsible for renal hypomagnesemia behaves as an inward-rectifying cation channel. Am J Physiol Renal Physiol 2008; 295: F91-F99.
38. Adalat S, Woolf AS, Johnstone KA et al. HNF1B mutations associate with hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol 2009; 20: 1123-1131.
39. Simon DB, Nelson-Williams C, Bia MJ et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996; 12: 24-30.
40. Nijenhuis T, Vallon V, van der Kemp AW et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005; 115: 1651-1658.
41. Hebert SC. Bartter syndrome. Curr Opin Nephrol Hypertens 2003; 12: 527-532.
42. Jeck N, Schlingmann KP, Reinalter SC et al. Salt handling in the distal nephron: lessons learned from inherited human disorders. Am J Physiol Regul Integr Comp Physiol 2005; 288: R782-R795.
43. Kobayashi K, Uchida S, Mizutani S et al. Intrarenal and cellular localization of CLC-K2 protein in the mouse kidney. J Am Soc Nephrol 2001; 12: 1327-1334.
44. Bockenhauer D, Feather S, Stanescu HC et al. Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med 2009; 360: 1960-1970.
45. Scholl UI, Choi M, Liu T et al. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc Natl Acad Sci USA 2009; 106: 5842-5847.
46. Renkema KY, Velic A, Dijkman HB et al. The calcium-sensing receptor promotes urinary acidification to prevent nephrolithiasis. J Am Soc Nephrol 2009.
47. Ferraro TN, Golden GT, Smith GG et al. Fine mapping of a seizure susceptibility locus on mouse chromosome 1: nomination of Kcnj10 as a causative gene. Mamm Genome 2004; 15: 239-251.
48. Neusch C, Rozengurt N, Jacobs RE et al. Kir4.1 potassium channel subunit is crucial for oligodendrocyte development and in vivo myelination. J Neurosci 2001; 21: 5429-5438.
49. Marcus DC, Wu T, Wangemann P et al. KCNJ10 (Kir4.1) potassium channel knockout abolishes endocochlear potential. Am J Physiol Cell Physiol 2002; 282: C403-C407.
50. Ito M, Inanobe A, Horio Y et al. Immunolocalization of an inwardly rectifying K+ channel, K(AB)-2 (Kir4.1), in the basolateral membrane of renal distal tubular epithelia. FEBS Lett 1996; 388: 11-15.
51. Katz AI, Doucet A, Morel F. Na-K-ATPase activity along the rabbit, rat, and mouse nephron. Am J Physiol 1979; 237: F114-F120.
52. Stokes JB, Walder RY, Kirby PA et al. Consequences of disrupting the Trpm6 gene in mice. J Am Soc Nephrol book 2008; 19: 48A; abstract #210.